U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 15 results

Status:
US Approved Rx (2019)
First approved in 1993

Class (Stereo):
CHEMICAL (ACHIRAL)



Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Previously Marketed
First approved in 1991

Class (Stereo):
CHEMICAL (ACHIRAL)



Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolo...
Status:
US Previously Marketed
First approved in 1952

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Methbarbital is a barbiturate anticonvulsant, discovered by Merck in 1905. It was introduced to market for treatment of epolepsy by Abbott in 1952, and discontinued in 1990.
Status:
US Approved Rx (2019)
First approved in 1993

Class (Stereo):
CHEMICAL (ACHIRAL)



Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

Showing 1 - 10 of 15 results